Per supplement-era user cohorts and modern UGL community reports at 10-30 mg/day:

• Day 3-7: Strength surge, increased aggression / "on edge" feeling, scale weight up 2-5 lb (primarily glycogen — no water retention because non-aromatizing). Subjective sense of "hardness" and vascularity. BP creep typically begins by day 4-5.
• Week 1-2: Continued strength gains, dry/lean look intensifying. ALT/AST detectably elevated by day 10. HDL crashing rapidly. BP elevation 10-20 mmHg above baseline common. Sleep disruption common (CNS arousal + BP elevation).
• Week 2-4: Plateau onset. LFTs often peak in this window — ALT 3-5× ULN typical, sometimes much higher. Cholestatic injury onset most commonly presents weeks 2-6 — pruritus without rash, dark urine, light stool, RUQ pain, jaundice, weight loss, severe fatigue. Any of these signs requires immediate cessation and ED evaluation. HDL crash often 60-80% of baseline. HCT climbing.
• Week 4-6 (if continued — strongly inadvisable): Diminishing returns vs. sharply accelerating side-effect curve. Most published case reports of severe DILI involved users who pushed past 4 weeks. Some published cases involved users at exactly the supplement-bottle-recommended 4 weeks.
• Post-cycle: Strength + scale weight retention better than dianabol/anadrol (because gain is less water-driven). HPG suppression established; testicular atrophy, low T, impaired libido for 8-16 weeks. PCT 4-6 weeks. LFTs may take 8-16 weeks to normalize in users who developed DILI signs on cycle. Lipids typically 12-24 weeks. HPG axis 12-24 weeks. Cholestatic injury can present or worsen up to 4-8 weeks AFTER cessation — this is a documented pattern.
• Mood / cognitive: Aggression / mood lability common. "On edge," conflict-seeking, sleep disruption. Some users report subjective focus / drive boost, others describe pure irritability. CNS arousal effect.
• Libido: High during cycle (androgenic surge), often low post-cycle during HPG recovery.

Reality check for combat sport: Superdrol's "dry, hard" profile is theoretically appealing for combat sport (less water-retention liability than dianabol/anadrol). But the hepatotoxicity, BP elevation, mood instability, and detection windows make this academically interesting at best. The case-report cluster makes any use uniquely high-risk among oral AAS. For a 20yo MMA athlete: do not use.

• Tolerance buildup: Real and rapid for the anabolic signal — strength gains plateau by week 3-4 even at constant dose. Receptor downregulation + HPG suppression. There is no protocol to "blast through" the plateau without dose escalation, which compounds toxicity non-linearly. Superdrol's risk curve gets dramatically worse past 4 weeks; dose escalation is uniquely poor risk-reward.
• Cycle length: NEVER >6 weeks oral; 2-4 weeks is the prudent ceiling. This is the shortest cycle ceiling of any oral AAS. Most prudent runs are 2-3 weeks. Some run 4 weeks at 10 mg/day. The hepatic-injury risk curve steepens past 4 weeks, faster than for dianabol or anadrol.
• Washout: Minimum 16 weeks before next 17αAA exposure of any kind (longer than typical due to hepatotoxicity ceiling). Liver enzymes should return to baseline; lipid panel should normalize; HPG axis should recover. Re-exposure in users who had any DILI signs is a hard contraindication.
• Bridging / "blast and cruise": Some bodybuilding protocols run continuous orals. Don't. Acute hepatic failure cases overwhelmingly cluster in continuous-oral users, and Superdrol is the worst candidate for this approach.
• Re-cycling: Possible in principle but each oral exposure compounds cumulative hepatic burden. The user should run zero cycles. Even adult bodybuilding consensus is 1 oral cycle per year max for Superdrol specifically.

Synergistic (in bodybuilding context — none recommended for the user)

• testosterone (injectable T-enanthate / T-cypionate). Standard kickstart pair. Superdrol weeks 1-3 (rapid early gains, dry profile), Test-E 400-500 mg/week weeks 1-12 (sustained anabolic). The synergy is real (mechanism-additive AR signaling); it does not address the dominant Superdrol hepatic risk. The injectable T does nothing for the C17α-alkyl-driven cholestatic injury.
• HCG (250-500 IU 2× weekly). Maintains testicular volume / Leydig responsiveness during cycle; eases PCT.

Required (harm-reduction floor; NOT safety)

• tudca — Tauroursodeoxycholic acid 500-1500 mg/day. Most-cited liver-protection adjunct. Mechanism: improves bile flow, displaces hydrophobic bile acids, reduces cholestatic stress — directly relevant to Superdrol's mechanism of injury (BSEP/MRP2 inhibition). Animal + small human data in cholestatic disease support the mechanism. Does NOT make Superdrol safe. Multiple Superdrol DILI case reports occurred in users running TUDCA. Reduces risk envelope; does not eliminate it.
• NAC (N-acetylcysteine) 1.2-2.4 g/day. Glutathione precursor; supports phase-II hepatic detoxification. Same caveat as TUDCA — risk-narrowing, not risk-eliminating. Best paired with TUDCA + milk thistle for the harm-reduction floor.
• Milk thistle (silymarin) 200-600 mg/day. Older harm-reduction standard. Weaker evidence than TUDCA/NAC for Superdrol-specific protection. Doesn't hurt; modest additive benefit.

Avoid stacking with

• Other 17α-alkylated AAS (oxandrolone, stanozolol, methyltestosterone, oxymetholone (Anadrol), methandienone (Dianabol), fluoxymesterone, danazol). Never stack two oral 17αAAs. Acute hepatic failure cluster. Superdrol particularly because of arguably worst-in-class hepatic injury rate — adding a second 17αAA on top of Superdrol is among the most hepatotoxic recreational protocols possible.
• Alcohol. Dramatically additive hepatic load. Multiple Superdrol DILI case reports involved concurrent alcohol use as accelerator.
• Acetaminophen / paracetamol at chronic dose. Even therapeutic-dose acetaminophen meaningfully adds to hepatic burden when combined with Superdrol.
• Statins. Compounding lipid disruption + hepatic load. Superdrol crashes HDL on its own; statins compound the hepatic risk without addressing the underlying cause.
• Anticoagulants (warfarin, DOACs). AAS class effect — potentiates anticoagulant action and raises bleeding risk.
• NSAIDs (chronic). Compounding hepatic + renal load. Relevant for combat athletes who use chronic NSAIDs for joint/training pain.
• High-dose stimulants / DMAA-era preworkouts. Compounding BP/CV strain. The 2008-2012 ER cluster of CV events in young bodybuilders involved Superdrol + DMAA-era preworkout combinations.
• Aromatase inhibitors (anastrozole, letrozole) on a Superdrol-only cycle. Mechanically irrelevant (Superdrol doesn't aromatize); over-suppression of E2 from background T conversion crashes joint health, libido, lipids. AIs only make sense if Superdrol is stacked with aromatizable injectable T.

Neutral / safe co-administration

• The user's existing V4 stack (DHA, Magtein, Citicoline, NAC, PS, Mg Glycinate, Curcumin Phytosome, Rhodiola, L-Theanine, Glycine/L-Tryptophan, D3+K2, Beta-Alanine, Vit C, creatine) — none would directly increase Superdrol risk; some (NAC, curcumin, omega-3) are part of the harm-reduction floor.
• Modafinil — neutral. No known interaction. Modafinil shares hepatic metabolism — minor additive load.

• CYP450: Methasterone is metabolized via hepatic 6β-hydroxylation (CYP3A4) and Phase II conjugation pathways (which are partially blocked by the doubly-methylated structure). CYP3A4 inducers (rifampicin, carbamazepine, St. John's wort) may reduce levels modestly; CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit) may raise levels. Clinical significance modest at typical doses; not a primary concern given the dominant hepatotoxicity issue.
• Anticoagulants: Potentiates warfarin and likely DOACs. Monitor INR closely if combined.
• Insulin / oral diabetic agents: Reduces insulin sensitivity at supraphysiologic dose; may require dose adjustment for diabetics.
• Cyclosporine / tacrolimus: AAS may raise levels via CYP3A4 effects. Avoid combination given hepatic load.
• Hepatically cleared drugs at therapeutic dose: Add hepatic load on top of cholestatic baseline. Avoid where possible.
• Hormonal contraceptives: No clinical interaction at typical dose. Not relevant for the user.
• Levothyroxine: AAS may alter thyroid binding globulin and free T4 levels modestly. Recheck TSH if both running.
• Statins: Compounding hepatic + lipid load; avoid.

Superdrol is one of the few AAS with a known pharmacogenomic susceptibility factor. El Sherrif 2014 (Liver Int, PMID 24190502) explored ATP8B1/ABCB11 polymorphisms in their case series of four bodybuilders with severe Superdrol-induced cholestatic injury. Findings:

• ATP8B1 variants (mild subclinical PFIC1-spectrum) — patients with mild BSEP-dysfunction baseline develop dramatic cholestatic injury under Superdrol exposure that they would not develop under dianabol or oxymetholone. The 2α-methyl + 17α-methyl combination appears to particularly stress BSEP function.
• ABCB11 variants (BSEP polymorphism spectrum) — same pattern; subclinical BSEP dysfunction unmasked by Superdrol exposure.

For the user (June 2026 23andMe + bloodwork): ATP8B1 / ABCB11 / ABCC2 variants are not currently part of consumer-grade 23andMe reporting. Even if they were, the answer is "don't run Superdrol." The pharmacogenomic angle reinforces the verdict; it doesn't introduce a hypothetical scenario where the verdict flips.

Other indirect:

• UGT1A1 variants (Gilbert's syndrome, ~5-10% population) — already-elevated unconjugated bilirubin baseline; Superdrol's cholestatic stress could push into clinically apparent jaundice faster.
• HLA-B alleles — emerging evidence for AAS DILI susceptibility; not yet specific for methasterone.
• CYP3A4 ultra-rapid or poor metabolizer variants could shift methasterone clearance modestly; small relative to dose-range variability from UGL product.

For the user: No specific pharmacogenomic switch flips this from SKIP-AT-20 to anything else. The presence of any BSEP/MRP2 susceptibility variant would make Superdrol exposure catastrophic; the absence does not make it safe.

For the user, none of these paths are recommended. Schedule III possession is a federal felony post-DASCA 2014. UGL tablets carry counterfeit + dosing + contamination risk on top of the inherent compound risk. International gray-market import is import-illegality. The compound is structurally inappropriate for the user regardless of source — the hepatotoxicity argument is dominant.

Cost estimate (academic only): A 4-week cycle at 20 mg/day = 28 days × 20 mg = ~560 mg total = ~56 tabs of 10 mg = $50-170 UGL. Trivial compared to the cost of a hepatic injury, an athletic commission failure, a felony charge, or a career-ending sanction. The cost-benefit is comically inverted.

(For documentation only. The user's biomarker plan does not include monitoring during Superdrol use because there is no Superdrol use planned.)

If a hypothetical AAS-using user wanted a defensible monitoring plan for Superdrol specifically:

Baseline (before any cycle):

• ALT, AST, GGT, alkaline phosphatase, total + direct bilirubin (bilirubin is the CRITICAL biomarker — cholestatic injury pattern means bilirubin rises before ALT/AST in some cases)
• Lipid panel — HDL-C, LDL-C, total cholesterol, triglycerides
• CBC with differential — hemoglobin, hematocrit
• CMP — creatinine, eGFR, fasting glucose (renal injury documented alongside hepatic)
• HbA1c
• Total + free testosterone, LH, FSH, sensitive estradiol, SHBG, prolactin
• BP — at-home monitoring, 7-day average (Superdrol drives BP elevation)
• Resting HR
• hsCRP

On cycle (week 1, week 2, week 4 — more frequent than other AAS given hepatotoxicity profile):

• ALT, AST, bilirubin (CRITICAL), GGT, alkaline phosphatase — primary safety panel; cholestatic pattern is the worry
• Lipid panel
• CBC (hematocrit watch >52%)
• BP weekly at home
• Symptom log — cholestasis signals (jaundice, pruritus, dark urine, light stool, RUQ pain, weight loss, fatigue)

Stop signs requiring immediate cessation (more conservative thresholds than other AAS):

• ALT or AST >3× ULN (more conservative than 5× ULN for other AAS — given Superdrol's hepatic profile)
• Bilirubin >2× ULN with rising GGT/AlkPhos — CRITICAL stop sign; cholestatic pattern
• Any jaundice, pruritus without rash, dark urine + light stool, RUQ pain → STOP IMMEDIATELY, ED if jaundice
• Sustained BP >150/95
• Hematocrit >55%
• Mood instability beyond tolerance

Post-cycle (week 2, 4, 6, 8, 12):

• Continued LFT monitoring weeks 2-8 post-cessation — Superdrol DILI can present or worsen up to 8 weeks AFTER stopping. This is unique among oral AAS.
• Full baseline panel + LH/FSH for HPG-axis recovery monitoring
• Lipid panel — should normalize within 12-24 weeks
• Liver panel — should normalize within 8-16 weeks; if anything fails to normalize by week 16, escalate to hepatology
• If bilirubin stays elevated post-cessation: hepatology referral, consider liver MRCP / ultrasound to assess for cholestatic injury and rule out structural complications